We performed anti-SARS-CoV-2 S1 IgG and IgA ELISAs by using β-versions of 2 commercial kits (EUROIMMUN Medizinische Labordiagnostika AG, https://www.euroimmun.com) and performed the assay according to the manufacturer’s protocol. We detected optical density (OD) at 450 nm and calculated a ratio of the reading of each sample to the reading of BackgroundAfter exposure to SARS-CoV-2 and/or vaccination there is an increase in serum antibody titers followed by a non-linear waning. Our aim was to find out if this waning of antibody titers would fit to a mathematical model.MethodsWe analyzed anti-RBD (receptor binding domain) IgG antibody titers and the breakthrough infections over a ten-month period following the second dose of the mRNA The Roche Elecsys ® Anti SARS-CoV-2 (“Elecsys” in short form) assay, our reference assasy, uses a recombinant protein representing the nucleocapsid (N) antigen for the determination of IgG For the extended evaluation, an additional 592 serum samples were obtained from those with previous PCR-confirmed SARS-CoV-2 infection that were used for the different verifications of the higher-throughput platforms (including a head-to-head study ) were tested using the Euroimmun anti-SARS-CoV-2 IgG assay Fig. 1 (right panel). Titers of SARS-CoV-2 IgM and IgG. The time courses for the serum titers of SARS-CoV-2 IgM and IgG at each time point (number of days after symptom onset) are shown in Fig. 1.Only data for which AVM5sL.

anti sars cov 2 igg kuantitatif